Grove Bank & Trust’s Genmab GMAB Stock Holding History

Grove Bank & Trust’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-42	Closed	-$1.02K	–	815
2024 Q3	$1.02K	Buy	+42	New	+$1.12K	﹤0.01%	708

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Grove Bank & Trust's GMAB Position: Q4 2024 in Review

Grove Bank & Trust sold out of Genmab (GMAB) in Q4 2024, closing a stake of 42 shares — an estimated $1.02K sold.

Grove Bank & Trust first reported a position in GMAB in Q3 2024 and held it in 1 quarter. The position peaked at $1.02K in Q3 2024. 228 funds tracked by Wall St. Rank hold GMAB as of Q4 2024.

Grove Bank & Trust reported no remaining Genmab position as of Q4 2024 after selling out during the quarter.
Grove Bank & Trust sold 42 Genmab shares in Q4 2024, an estimated $1.02K.
Grove Bank & Trust first reported a position in Genmab in Q3 2024 and held it in 1 quarter.
Grove Bank & Trust's Genmab position peaked at $1.02K in Q3 2024.
228 funds tracked by Wall St. Rank held Genmab as of Q4 2024.

Based on Grove Bank & Trust's 13F filing for Q4 2024, filed 16 Jan 2025.